Literature DB >> 24379140

MDM2 SNP309T>G polymorphism and hepatocellular carcinoma risk: a meta-analysis.

Qi-Wen Chen1, Hao Chen, Jian-Shan Cheng, Zhi-Qiang Meng.   

Abstract

Case-control studies on the association between mouse double-minute 2 homolog (MDM2) SNP309T>G polymorphism and hepatocellular carcinoma have provided either controversial or inconclusive results. To clarify the effect of MDM2 SNP309T>G polymorphism on the risk of hepatocellular carcinoma, a meta-analysis of all case-control observational studies was performed. Pooled odds ratios (ORs) for various polymorphisms were estimated using random and fixed effects models. The Q-statistic was used to evaluate the homogeneity, and Egger and Begg tests were used to assess publication bias. Overall, the MDM2 SNP309T>G polymorphism was associated with a risk of hepatocellular carcinoma (OR = 0.68; 95% CI = 0.54-0.85 for allele contrast, p = 0.0005, phet = 0.004). The contrast of homozygotes and the recessive and dominant models produced the same pattern of results as the allele contrast. In the analysis stratified by ethnicity, significant associations were found in the Caucasian population in all of the genetic models. In addition, heterogeneity disappeared in subgroups of Caucasian subjects. Our pooled data suggest evidence for a major role of MDM2 SNP309T>G polymorphism in the carcinogenesis of hepatocellular carcinoma, especially among Caucasian populations.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24379140     DOI: 10.1007/s13277-013-1543-z

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  22 in total

1.  Mapping of the p53 and mdm-2 interaction domains.

Authors:  J Chen; V Marechal; A J Levine
Journal:  Mol Cell Biol       Date:  1993-07       Impact factor: 4.272

Review 2.  The p53-mdm2 autoregulatory feedback loop: a paradigm for the regulation of growth control by p53?

Authors:  S M Picksley; D P Lane
Journal:  Bioessays       Date:  1993-10       Impact factor: 4.345

3.  Protein expression of MDM2 and its clinicopathological relationships in human hepatocellular carcinoma.

Authors:  K Endo; T Ueda; T Ohta; T Terada
Journal:  Liver       Date:  2000-06

Review 4.  Primary liver cancer: worldwide incidence and trends.

Authors:  F Xavier Bosch; Josepa Ribes; Mireia Díaz; Ramon Cléries
Journal:  Gastroenterology       Date:  2004-11       Impact factor: 22.682

5.  MDM2 SNP309T>G polymorphism increases susceptibility to hepatitis B virus-related hepatocellular carcinoma in a northeast Han Chinese population.

Authors:  Xi Wang; Xuelong Zhang; Bing Qiu; Yinhua Tang; He Sun; Hongfei Ji; Yan Liu; Lijun Shi; Guang Song; Youlin Yang
Journal:  Liver Int       Date:  2012-03-14       Impact factor: 5.828

6.  MDM2 SNP309T>G polymorphism and risk of hepatocellular carcinoma: a case-control analysis in a Moroccan population.

Authors:  Sayeh Ezzikouri; Abdellah Essaid El Feydi; Rajae Afifi; Latifa El Kihal; Mustapha Benazzouz; Mohammed Hassar; Agnès Marchio; Pascal Pineau; Soumaya Benjelloun
Journal:  Cancer Detect Prev       Date:  2009-02-23

7.  MDM2 SNP309 variation contributes to leukemia risk: meta-analyses based on 7259 subjects.

Authors:  Wenlei Zhuo; Liang Zhang; Junjun Ling; Bo Zhu; Zhengtang Chen
Journal:  Leuk Lymphoma       Date:  2012-06-12

8.  MDM2 and p53 polymorphisms are associated with the development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection.

Authors:  Young Joon Yoon; Hye Young Chang; Sang Hoon Ahn; Ja Kyung Kim; Yong Kwang Park; Dae Ryong Kang; Jun Yong Park; Sung Min Myoung; Do Young Kim; Chae Yoon Chon; Kwang-Hyub Han
Journal:  Carcinogenesis       Date:  2008-04-04       Impact factor: 4.944

9.  TP53 and MDM2 gene polymorphisms and risk of hepatocellular carcinoma among Italian patients.

Authors:  Valeria Di Vuolo; Luigi Buonaguro; Francesco Izzo; Simona Losito; Gerardo Botti; Franco M Buonaguro; Maria Lina Tornesello
Journal:  Infect Agent Cancer       Date:  2011-08-15       Impact factor: 2.965

10.  Association of MDM2 SNP309 variation with lung cancer risk: evidence from 7196 cases and 8456 controls.

Authors:  Wenlei Zhuo; Liang Zhang; Bo Zhu; Junjun Ling; Zhengtang Chen
Journal:  PLoS One       Date:  2012-07-23       Impact factor: 3.240

View more
  5 in total

1.  Association between KIF1B rs17401966 polymorphism and hepatocellular carcinoma risk: a meta-analysis involving 17,210 subjects.

Authors:  Zhe Zhang
Journal:  Tumour Biol       Date:  2014-06-22

2.  Interaction between p53 codon 72 and MDM2 309T>G polymorphisms and the risk of hepatocellular carcinoma.

Authors:  Moqin Qiu; Yingchun Liu; Xiangyuan Yu; Linyuan Qin; Chunhua Bei; Xiaoyun Zeng; Xiaoqiang Qiu; Bo Tang; Songqing He; Hongping Yu
Journal:  Tumour Biol       Date:  2015-10-17

3.  MDM2 SNP309 variation confers the susceptibility to hepatocellular cancer: a meta-analysis based on 4271 subjects.

Authors:  Jinli Lv; Bo Zhu; Liang Zhang; Qichao Xie; Wenlei Zhuo
Journal:  Int J Clin Exp Med       Date:  2015-04-15

4.  Autoantibody response to murine double minute 2 protein in immunodiagnosis of hepatocellular carcinoma.

Authors:  Mei Liu; Su-jun Zheng; Yu Chen; Ning Li; Peng-fei Ren; Li-ping Dai; Zhong-ping Duan; Jian-Ying Zhang
Journal:  J Immunol Res       Date:  2014-05-14       Impact factor: 4.818

5.  Modifying effect of mouse double minute-2 promoter variants on risk of recurrence for patients with squamous cell carcinoma of oropharynx.

Authors:  Yang Zhang; Erich M Sturgis; Yuncheng Li; Qingyi Wei; Zhigang Huang; Guojun Li
Journal:  Sci Rep       Date:  2017-01-03       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.